( EuronextBrussels:THR )

News from ThromboGenics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 10, 2017, 06:23 ET ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement

ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB ("BioInvent") (OMXS: BINV) today announce that they have agreed to amend...


Jun 08, 2017, 01:30 ET ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress, Barcelona, Spain

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it...


May 24, 2017, 01:30 ET ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it...


May 11, 2017, 11:40 ET ThromboGenics Business Update - Q1 2017

Progressing Innovative Diabetic Eye Disease Clinical and Pre-Clinical Portfolio Highlights - ThromboGenics continues to focus on...


May 02, 2017, 01:30 ET New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that its...


Apr 20, 2017, 01:30 ET ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema

ThromboGenics, a biotechnology company focusing on novel treatments for back of the eye disease and diabetic eye disease, announced it has...


Mar 16, 2017, 13:44 ET ThromboGenics Business Update - FY 2016

- Innovative Diabetic Eye Disease Clinical and Pre-Clinical Portfolio - Provides "Multiple Shots on Goal" - First Patients Enrolled in Phase...


Jan 10, 2017, 01:30 ET ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)

THR-317 could become an attractive alternative or add-on treatment for current anti-VEGF medicines when treating DME or DR ThromboGenics...


Oct 11, 2016, 11:40 ET Latest ThromboGenics' Clinical Data to be Presented at 2016 American Academy of Ophthalmology (AAO) Meeting in Chicago

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, today announces that the...


Sep 07, 2016, 10:40 ET ThromboGenics Presenting New Ophthalmic Research Data

ThromboGenics NV (Euronext Brussels: THR), a Belgium-based biopharmaceutical company developing novel medicines for back of the eye disease, with...


Aug 08, 2016, 01:30 ET ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye diseases, today announces that the...


Jun 08, 2016, 11:40 ET ThromboGenics Receives US FDA Approval for New 'Already-Diluted' Formulation of JETREA®

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for back of the eye disease, today...


Apr 27, 2016, 02:00 ET New Ocriplasmin Research Findings Presented

New Data Confirm Appropriate Patient Selection Leads to Improved Treatment Outcomes, With no new Safety Signals Observed  ThromboGenics NV...


Mar 01, 2016, 02:00 ET ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments...


Jan 13, 2016, 01:30 ET ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Assessing the potential of ocriplasmin to reduce risk of disease progression from NPDR to sight-threatening Proliferative Diabetic Retinopathy...


Dec 06, 2013, 18:03 ET ThromboGenics' Founder Prof Desire Collen Retiring as Chairman

Dr Staf Van Reet appointed as new Chairman of the Board ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company...


Dec 03, 2013, 01:30 ET J-Code for ThromboGenics' JETREA to Become Effective January 1, 2014

Permanent J-Code J7316 will lead to streamlined reimbursement of JETREA® in the US ThromboGenics NV (Euronext Brussels: THR), an integrated...


Nov 22, 2013, 10:05 ET ThromboGenics' Founder Prof Desire Collen Receives Scrip Lifetime Achievement Award

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...


Nov 20, 2013, 14:12 ET ThromboGenics' Partner Alcon Launches JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion in Canada

Canada is the first market launch for JETREA® outside the US and Europe ThromboGenics NV (Euronext Brussels: THR), an integrated...


Oct 17, 2013, 15:01 ET Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole

Decision confirms therapeutic benefits for treatment of VMT patients suffering from mild and moderate symptoms, or 94% of...


Oct 01, 2013, 12:52 ET Euretina Presentation "Adoption of JETREA® in My Everyday Practice" Confirms Need for a New Paradigm in Treatment of Symptomatic VMA/ VMT, Including Those Cases Associated with MH

Largest ever retrospective review of VMA/VMT patients confirms early treatment initiation may stop disease progression and lead to better visual...


Sep 30, 2013, 01:30 ET ThromboGenics Establishes Level 1 ADR Program for US Investors

ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic...


Sep 05, 2013, 01:30 ET ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema

ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic...


Sep 02, 2013, 12:14 ET UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA® for Treatment of Vitreomacular Traction and Macular Hole

  Metamorphopsia confirmed as a severe and distressing symptom deserving immediate attention and early treatment with reimbursement -...


Aug 29, 2013, 13:41 ET ThromboGenics Business Update H1 2013

Conference call and webcast scheduled today at 06:30 PM CET - 12:30 PM EST - Total H1 2013 revenue amounted to €102.7 million -...